← Back to All US Stocks

Agenus Inc. (AGEN) Fundamental Analysis & AI Grade 2026

AGEN Nasdaq Biological Products, (No Diagnostic Substances) DE CIK: 0001098972
Updated This Month • Analysis: May 13, 2026 • SEC Data: 2026-03-31
Combined AI Grade
D
88% Confidence
STRONG AGREEMENT
D
85% Conf
D
92% Conf

📊 AGEN Key Takeaways

Revenue: $33.7M
Net Margin: 116.1%
Free Cash Flow: $-36.0M
Current Ratio: 0.38x
Debt/Equity: N/A
EPS: $1.02
AI Grade: D with 85% confidence
Agenus Inc. (AGEN) receives a D fundamental grade with 88% confidence from our AI analysis based on SEC 10-K filings. With revenue of $33.7M, net profit margin of 116.1%, Agenus Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete AGEN stock analysis for 2026.

Is Agenus Inc. (AGEN) a Good Investment?

Claude

Despite impressive headline earnings growth, AGENUS shows critical financial distress: negative stockholders' equity of -$221.2M, deteriorating liquidity (0.38x current ratio), and severe cash burn (-$36.0M operating cash flow). The 116.1% net margin and $24M gap between operating and net income indicate unsustainable non-operating gains masking fundamental operational stress.

ChatGPT

Agenus shows modest revenue growth, but the quality of that growth is weak because it is paired with deeply negative operating margins and heavy cash burn. The near-breakeven net income appears unsupported by core operations, while negative equity, very low cash, and weak liquidity point to significant financial stress and a high dependence on external financing.

Agenus Inc. Key Strengths (AGEN)

Claude
  • + Revenue growth of 10.4% YoY shows market demand
  • + Strong operating margin of 44.6% indicates pricing power in core operations
  • + Cash position of $35.0M provides near-term runway
ChatGPT
  • + Revenue grew 10.4% year over year, indicating continued commercial or collaboration activity
  • + Net loss narrowed sharply versus the prior year, showing headline earnings improvement
  • + Capital expenditure requirements are minimal, which limits additional fixed investment burden

AGEN Stock Risks: Agenus Inc. Investment Risks

Claude
  • ! Negative stockholders' equity of -$221.2M: balance sheet is technically insolvent
  • ! Operating cash flow of -$36.0M: company burns cash despite positive earnings (unsustainable)
  • ! Current ratio of 0.38x: severe liquidity crisis, cannot meet short-term obligations
  • ! Interest coverage of 0.5x: cannot service debt from operations
  • ! Net income driven by non-operating items, not sustainable operations
ChatGPT
  • ! Liquidity is extremely weak, with only $3.0M in cash and a 0.41x current ratio
  • ! Free cash flow and operating cash flow are deeply negative, indicating the business is not self-funding
  • ! Negative stockholders equity and weak interest coverage reflect a stressed balance sheet and elevated financing risk

Key Metrics to Watch

Claude
  • * Operating cash flow: must turn positive to demonstrate viable business
  • * Stockholders' equity: trajectory toward solvency critical
  • * Cash burn rate and runway: company survival depends on reaching cash flow breakeven
ChatGPT
  • * Quarterly operating cash burn relative to cash on hand
  • * Revenue durability and whether operating income improves toward sustained profitability

Agenus Inc. (AGEN) Financial Metrics & Key Ratios

Revenue
$33.7M
Net Income
$39.2M
EPS (Diluted)
$1.02
Free Cash Flow
$-36.0M
Total Assets
$186.5M
Cash Position
$35.0M

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

AGEN Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin 44.6%
Net Margin 116.1%
ROE N/A
ROA 21.0%
FCF Margin -106.6%

AGEN vs Healthcare Sector: How Agenus Inc. Compares

How Agenus Inc. compares to Healthcare sector averages

Net Margin
AGEN 116.1%
vs
Sector Avg 12.0%
AGEN Sector
ROE
AGEN 0.0%
vs
Sector Avg 15.0%
AGEN Sector
Current Ratio
AGEN 0.4x
vs
Sector Avg 2.0x
AGEN Sector
Debt/Equity
AGEN 0.0x
vs
Sector Avg 0.6x
AGEN Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Agenus Inc. Stock Overvalued? AGEN Valuation Analysis 2026

Based on fundamental analysis, Agenus Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
116.1%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Agenus Inc. Balance Sheet: AGEN Debt, Cash & Liquidity

Current Ratio
0.38x
Quick Ratio
0.38x
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
0.48x
Long-term Debt
$30.2M

AGEN Revenue & Earnings Growth: 5-Year Financial Trend

AGEN 5-year financial data: Year 2021: Revenue $295.7M, Net Income -$111.6M, EPS N/A. Year 2022: Revenue $295.7M, Net Income -$182.9M, EPS $-1.05. Year 2023: Revenue $295.7M, Net Income -$182.9M, EPS $-0.11. Year 2024: Revenue $156.3M, Net Income -$230.7M, EPS $-15.64. Year 2025: Revenue $156.3M, Net Income -$257.4M, EPS $-13.75.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Agenus Inc.'s revenue has declined by 47% over the 5-year period, indicating business contraction. The most recent EPS of $-13.75 indicates the company is currently unprofitable.

AGEN Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-106.6%
Free cash flow / Revenue

AGEN Quarterly Earnings & Performance

Quarterly financial performance data for Agenus Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $24.1M -$26.4M $1.02
Q3 2025 $25.1M $7.5M $0.37
Q2 2025 $23.5M -$26.4M $-1.00
Q1 2025 $24.1M -$26.4M $-1.03
Q3 2024 $24.3M -$54.8M $-3.08
Q2 2024 $23.5M -$54.8M $-2.52
Q1 2024 $22.9M -$63.5M $-3.04
Q3 2023 $22.8M -$49.2M $-0.16

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Agenus Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$36.0M
Cash generated from operations
Stock Buybacks
$606.0K
Shares repurchased (TTM)
Dividends
None
No dividend program

AGEN SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Agenus Inc. (CIK: 0001098972)

📋 Recent SEC Filings

Date Form Document Action
Jun 2, 2026 4 xslF345X06/ownership.xml View →
May 19, 2026 4 xslF345X06/ownership.xml View →
May 15, 2026 8-K agen-20260512.htm View →
May 11, 2026 10-Q agen-20260331.htm View →
May 11, 2026 8-K agen-20260511.htm View →

Frequently Asked Questions about AGEN

What is the AI rating for AGEN?

Agenus Inc. (AGEN) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are AGEN's key strengths?

Claude: Revenue growth of 10.4% YoY shows market demand. Strong operating margin of 44.6% indicates pricing power in core operations. ChatGPT: Revenue grew 10.4% year over year, indicating continued commercial or collaboration activity. Net loss narrowed sharply versus the prior year, showing headline earnings improvement.

What are the risks of investing in AGEN?

Claude: Negative stockholders' equity of -$221.2M: balance sheet is technically insolvent. Operating cash flow of -$36.0M: company burns cash despite positive earnings (unsustainable). ChatGPT: Liquidity is extremely weak, with only $3.0M in cash and a 0.41x current ratio. Free cash flow and operating cash flow are deeply negative, indicating the business is not self-funding.

What is AGEN's revenue and growth?

Agenus Inc. reported revenue of $33.7M.

Does AGEN pay dividends?

Agenus Inc. does not currently pay dividends.

Where can I find AGEN SEC filings?

Official SEC filings for Agenus Inc. (CIK: 0001098972) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is AGEN's EPS?

Agenus Inc. has a diluted EPS of $1.02.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is AGEN's fundamental grade?

Based on our AI fundamental analysis in June 2026, Agenus Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is AGEN stock overvalued or undervalued?

Valuation metrics for AGEN: ROE of N/A (sector avg: 15%), net margin of 116.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is AGEN's AI grade for 2026?

Our dual AI analysis gives Agenus Inc. a combined D grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.

What is AGEN's free cash flow?

Agenus Inc.'s operating cash flow is $-36.0M, with capital expenditures of $0.0. FCF margin is -106.6%.

How does AGEN compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin 116.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.38 (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% AVGO 87% DECK 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 13, 2026 | Data as of: 2026-03-31 | Powered by Claude AI